Centronuclear Myopathy
12
6
6
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
8.3%
1 terminated out of 12 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (12)
Molecular and Genetic Studies of Congenital Myopathies
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment
Multispectral Optoacoustic Tomography for Advanced Imaging of Centronuclear Myopathy
Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study
Myotubular and Centronuclear Myopathy Patient Registry
The Prevalence of RYR1-related Disease
The Natural History and Muscle Fatigability of Patients With Congenital Myopathies.
Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies
Prospective Natural History Study of Patients With Myotubular Myopathy and Other CentroNuclear Myopathies
Natural History Study of Patients With Centronuclear Myopathies
Early Phase Human Drug Trial to Investigate DYN101 in Participants 2 to 17 Years With Centronuclear Myopathies